FDA approves cinqair for severe asthma

FDA approves cinqair for severe asthma

(HealthDay)—Cinqair (reslizumab) has been approved by the U.S. Food and Drug Administration to treat severe asthma among adults 18 and older.

Cinqair, given by injection every four weeks, is designed to reduce attacks by reducing blood levels of eosinophils, the FDA said. The drug is to be used in combination with other medications, the agency noted.

In clinical studies involving an unspecified number of severe asthma patients, those who took Cinqair had fewer severe attacks than those who took a placebo, and a longer time to the first attack, the agency said. Users of Cinqair, a lab-developed interleukin-5 antagonist monoclonal antibody, also had improved lung function compared to a placebo.

The FDA warned, however, that Cinqair could cause severe hypersensitivity reactions that could be life threatening.

The drug is produced by Teva Pharmaceuticals, based in Frazer, Penn.

Explore further

Investigational drug can reduce asthma flareups

More information: More Information

Health News Copyright © 2016 HealthDay. All rights reserved.

Citation: FDA approves cinqair for severe asthma (2016, March 24) retrieved 24 January 2021 from https://medicalxpress.com/news/2016-03-fda-cinqair-severe-asthma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments